Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital boosted their Q2 2025 EPS estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $2.12 per share for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $2.02 EPS, FY2028 earnings at $1.44 EPS and FY2029 earnings at $1.76 EPS.

Several other research firms have also recently weighed in on ZVRA. Guggenheim upped their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Canaccord Genuity Group upped their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Trading Up 3.6%

ZVRA opened at $8.43 on Friday. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a 50-day simple moving average of $7.52 and a 200 day simple moving average of $8.07. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $460.94 million, a price-to-earnings ratio of -4.28 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $20.40 million during the quarter, compared to analysts’ expectations of $16.96 million. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

Insiders Place Their Bets

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the stock in a transaction on Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ZVRA. BNP Paribas Financial Markets acquired a new position in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC increased its stake in shares of Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after buying an additional 8,020 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zevra Therapeutics in the fourth quarter valued at approximately $94,000. Squarepoint Ops LLC increased its stake in shares of Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares during the period. Finally, ProShare Advisors LLC acquired a new position in shares of Zevra Therapeutics in the fourth quarter valued at approximately $145,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.